NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy-A randomized proof of concept study.
Eva TieckeMaurizio RainisioElon EisenbergJulio WainsteinEli KaplanMichal SilverbergLiat HochmanSara MangialaioPublished in: European journal of pain (London, England) (2022)
NRD.E1 is a novel non-opioid therapeutic which is being developed for the treatment of PDPN. In this randomized, controlled, dose-finding, Proof of Concept study, NRD.E1 induced a clinically relevant pain reduction and it was well tolerated. Available data suggest that NRD.E1 has at least similar efficacy and better tolerability than the currently available therapies, potentially offering a promising new therapeutic option to patients with PDPN and possibly other neuropathic pain indications.
Keyphrases
- neuropathic pain
- chronic pain
- pain management
- spinal cord
- spinal cord injury
- open label
- double blind
- placebo controlled
- high glucose
- type diabetes
- diabetic rats
- phase iii
- phase ii
- clinical trial
- electronic health record
- big data
- endothelial cells
- wound healing
- machine learning
- combination therapy
- randomized controlled trial